poisar

Stocks · News reference

YD Bio Publishes Review Article Titled Beyond Bone Health: Exploring The ‘Heart–Brain–Bone’ Axis Modulated By Lipid-Soluble Nutrients

Aug 25, 2026, 12:03 PMBenzinga Newsdesk

YD Bio Limited ("YD Bio" or the "Company") (Nasdaq: YDES), a biotechnology company advancing DNA methylation–based cancer detection technology and ophthalmologic innovations, today announced the

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

YDES
Source
benzinga
Observed
Aug 25, 2026, 12:03 PM
Checked
Aug 25, 2026, 12:03 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  3. Jul 2, 2026, 12:00 PMYd Bio Limited

    YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations

    YD Bio announced that its affiliate EG BioMed US obtained out-of-state clinical laboratory licenses in Rhode Island and Pennsylvania, expanding its CLIA-certified laboratory's authorized operating footprint to 46 U.S. states plus Washington D.C. and Guam. The expansion supports the company's DNA methylation-based early cancer detection operations and broadens patient access to blood-based testing services for various cancers.

    Read original at globenewswire-inc
    YDESYDESW